Table of Contents:
  • Levodopa in the treatment of Parkinson's disease
  • Changing dopamine agonist treatment in Parkinson's disease : experiences with switching to pramipexole
  • The DONPAD-study - treatment of dementia in patients with Parkinson's disease with donepzil
  • PD-related psychosis : pathophysiology with therapeutical strategies
  • Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's disease
  • Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines - implications for the CNS
  • Molecular mechnaism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease : possible implications of glial cells
  • Involvement of type A monoamine oxidase in neurodegeneration : regulation of mitochondrial signaling leading to cell death or neuroprotection
  • The relationship of early studies of monoamines oxidase to present concepts
  • Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson's disease induced by the Japanese encephalitis virus
  • Isatin interation with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs : partial agnoism with deprenyl
  • Inhibition of amine oxidases by the histamine-1 receptor antagnoist hydroxyzine
  • Neuroprotection for Parkinson's disease
  • Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection
  • Assessing neuroprotection in Parkinson's disease : from the animal models to molecular neuroimaging in vivo
  • Deprenyl : from chemical synthesis to neuroprotection
  • The use of rasagiline in Parkinson's disease
  • Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress : potential candidates for the control of neurodegenerative diseases
  • Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain
  • Long lasting effects on infancy iron deficiency - preliminary results
  • Altered regulation of iron transport and storage in Parkinson's disease
  • Iron dyshomeostasis in Parkinson's disease
  • Cerebral oligemia and iron influence in cerebral structures - element of Morbus Parkinson models
  • Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy
  • Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a pierazine chelator
  • Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain